Abstract
Aim: We aimed to describe opioid maintenance treatment (OMT) to pregnant women in Norway and study thebackground characteristics of the pregnant women compared to the general population of pregnant women andto a previous clinical cohort study of OMT in pregnancy.Methods: Population-based cohort study with linked data from the Norwegian Medical Birth Registry, theNorwegian Prescription Database, the Norwegian Patient Registry, and Statistics Norway. The study populationconsisted of women giving birth between 2005-2015 in Norway. We defined OMT pregnancies as pregnancieswhere the woman was dispensed OMT medications (methadone, buprenorphine, or buprenorphine/naloxone) at least once during pregnancy.Results: The study population consisted of 420,808 women with 645,440 pregnancies ending in a live birth inNorway in 2005-2015 (the general pregnant population). Of these, 261 women (0.6‰) had altogether 306OMT pregnancies. The mean number of pregnancies was 28 OMT pregnancies per year and quite stable duringthe study period. Women with OMT pregnancies were older, smoked tobacco more frequently, had lowereducation, and fewer of them had a partner, compared to the general population of pregnant women. In mostpregnancies, the women were treated with buprenorphine (n=183 (59.8%)), while in 120 (39.2%) pregnancies,the woman received methadone. From 2008, buprenorphine replaced methadone as the most frequently useddrug. In only 38 (12.4%) pregnancies, OMT treatment was initiated in pregnancy. In 201 (66%) pregnancies,the woman used OMT medications in all trimesters. For these women, the mean amount of dispensed drug was3.4 DDD/day (85 mg/day) in pregnancy for methadone and 1.9 DDD/day (15.2 mg/day) for buprenorphine.Conclusion: The number of OMT pregnancies per year has been low and stable in the period 2005-2015.Following Norwegian recommendations, there has been a shift from treatment with methadone towardsbuprenorphine. The women receiving OMT during pregnancy had more risk factors for adverse outcomes thanthe general pregnant population but were quite similar to the previous clinical cohort.
Highlights
Opioid maintenance treatment (OMT) has been recommended as the standard care for opioid use disorder since the late 1990s in Norway [1]
Maternal opioid use disorder during pregnancy is associated with a range of adverse obstetric and neonatal outcomes [7]
Using the unique nationwide registry data in Norway, we aimed to describe the pharmacological part of OMT given to this patient group focusing on initiation of OMT in pregnancy, type and amount of OMT medication, and timing according to trimesters
Summary
Opioid maintenance treatment (OMT) has been recommended as the standard care for opioid use disorder since the late 1990s in Norway [1]. In a Norwegian setting, OMT has been shown to reduce mortality, morbidity, criminality, and improve the patients’ quality of life [2,3,4,5]. Maternal opioid use disorder during pregnancy is associated with a range of adverse obstetric and neonatal outcomes [7]. The introduction of methadone maintenance treatment in the late 1960s in the US resulted in fewer obstetric complications, neonatal morbidity, and mortality compared to illicit heroin use during pregnancy [8,9,10]. The World Health Organization (WHO) recommends that methadone or buprenorphine should be maintained during pregnancy if a woman in OMT becomes pregnant [11]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
